1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6EEBEEFFCCEC3A32D65257BAC004B1895
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/medical-affairs-in-India-structure-and-challenges-in-emerging-markets?opendocument
18
19opendocument
203.226.251.81
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Structure, Staffing and Budgets

Building Best-in-Class Medical Affairs Capabilities In India – Structure and Challenges in Emerging Markets

ID: 5261


Features:

18 Info Graphics

9 Data Graphics

60+ Metrics

7 Narratives


Pages/Slides: 35


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Building Best-in-Class Medical Affairs Capabilities In India – Structure and Challenges in Emerging Markets"


STUDY OVERVIEW

Pharmaceutical Medical Affairs organizations bridge the gap between commercial and R&D operations and hence are critical for biopharma and medical device organization future growth. In fact, the call for increased transparency in the recent years has increased the responsibility of Medical Affairs at many companies. However, Medical Affairs at many companies in emerging countries, especially India, is still in its infancy. Moreover, Medical Affairs groups in India lack clear value proposition to evolve beyond their traditional role.

Best Practices, LLC's recent case study illustrates how mature and Indian biopharmaceutical companies are structuring and managing their Medical Affairs organizations today. The study also reviews the regulatory landscape in India and the key challenges facing Medical Affairs groups there.

KEY TOPICS

  • Medical Affairs: Scope & Structure
  • Medical Affairs: Leadership & Oversight
  • Medical Affairs: Regulatory Landscape & Challenges
  • Participant Demographic Data

SAMPLE KEY METRICS
  • Medical Affairs group dedication
  • Departmental reporting relationships
  • Job level or Medical Affairs head
  • Geographic span of organization
  • Top three success factors for developing and maintaining effective Medical Affairs group
  • Top three challenges for developing and maintaining effective Medical Affairs group

SAMPLE KEY FINDINGS
  • Mature Market Medical Affairs Reporting into R&D, Becoming Own Entity; India Medical Affairs Reporting to Commercial: Four out of 10 mature market groups in the benchmark class report to R&D. As a function, Medical Affairs tends to more aligned with R&D, reflecting a common drive to differentiate itself from the commercial side of the organization. However, half of India segment participants report into Commercial/Marketing highlighting the fact that MA in India is still in formative stages.

STUDY METHODOLOGY


This study engaged executives from 50 leading healthcare companies. Segmentation analysis was key to examining trends and effective practices. Within the Mature Markets Segment, 41 participants make up the Pharmaceutical Segment, while the Medical Device Segment consists of 12 participants. The India Segment consists of 8 companies working actively in the India market.

Industries Profiled:
Pharmaceutical; Biotech; Health Care; Biopharmaceutical; Diagnostic; Laboratories; Chemical; Technology; Medical Device; Manufacturing; Financial Services; Consumer Products


Companies Profiled:
Pfizer; LifeCell; Biocon; Biogen Idec; Alkem; AstraZeneca; Ipsen; Esteve; Guerbet; Endo Pharmaceuticals; Allergan; BD; Methapharm; GlaxoSmithKline ; Gilead Sciences; Ethicon; Johnson & Johnson; Mylan; Forest Laboratories; MedImmune; Upsher-Smith; Grunenthal; Phillips; Sandoz; Baxter International; ONYX; Xanodyne Pharmaceuticals; ViroPharma; Ranbaxy; Bristol-Myers Squibb; Novartis; Medtronic; Astellas; GE Healthcare; Eisai; Roche; Teva Pharmaceutical Industries Ltd; MSD; Bayer; Boehringer Ingelheim; Shire; Novo Nordisk; Sanofi Pasteur; Genentech; Cubist Pharmaceuticals; UCB Pharma; Sunovion; Valeant

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.